Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

• Główni autorzy: Hayder M. Al-Kuraishy (Autor), Ali I. Al-Gareeb (Autor), Sarah M. Albogami (Autor), Sabatier Jean-Marc (Autor), Eman Hassan Nadwa (Autor), Amin A. Hafiz (Autor), Walaa A. Negm (Autor), Marwa Kamal (Autor), Mohammed Al-Jouboury (Autor), Engy Elekhnawy (Autor), Gaber El-Saber Batiha (Autor), Michel De Waard (Autor)
• Format: Książka
• Wydane: MDPI AG, 2022-11-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study,...